Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free UPC Stock Alerts

Universe Pharmaceuticals (UPC) Financials

Universe Pharmaceuticals logo
$5.65 -0.22 (-3.75%)
Closing price 04:00 PM Eastern
Extended Trading
$5.73 +0.08 (+1.42%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Universe Pharmaceuticals

Annual Income Statements for Universe Pharmaceuticals

This table shows Universe Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 7.45 7.41 11 -7.91 -6,581 -8,727 -3,672
Consolidated Net Income / (Loss)		 7.55 7.56 11 -7.91 -6,581 -8,727 -3,672
Net Income / (Loss) Continuing Operations		 7.45 7.41 11 -7.91 -6,581 -8,727 -3,672
Total Pre-Tax Income 		9.65 10 14 -7.09 -4,327 -8,121 -3,672
Total Operating Income		 9.75 10 14 -7.02 -3,966 -8,020 -2,916
Total Gross Profit		 13 14 25 22 10,315 6,072 6,301
Total Revenue		 33 31 48 40 32,309 23,024 17,859
Operating Revenue		 - - 48 40 32,309 23,024 17,859
Total Cost of Revenue		 20 17 23 18 21,994 16,953 11,558
Operating Cost of Revenue		 20 17 23 18 21,994 16,953 11,558
Total Operating Expenses		 3.65 3.84 12 29 14,281 14,092 9,698
Selling, General & Admin Expense		 3.04 3.26 6.27 21 9,423 11,061 8,545
Research & Development Expense		 0.62 0.58 5.47 7.64 4,859 3,031 672
Impairment Charge		 - - - - - - 481
Total Other Income / (Expense), net		 -0.20 -0.25 -0.01 -0.07 -361 -101 -275
Interest Expense		 0.13 0.12 0.10 0.16 157 278 232
Interest & Investment Income		 0.03 0.02 - 0.04 31 32 65
Other Income / (Expense), net		 -0.10 -0.15 0.09 0.05 -236 145 -108
Income Tax Expense		 2.10 2.54 2.36 0.82 2,254 607 0.00
Basic Earnings per Share		 - $0.47 $3.58 ($1,309.11) ($1,089.21) ($626.96) ($8.06)
Weighted Average Basic Shares Outstanding		 16M 16M 3.16M 6.04K 6.04M 13.92M 455.87M
Diluted Earnings per Share		 - - - ($1,309.11) ($1,089.21) ($626.96) ($8.06)
Weighted Average Diluted Shares Outstanding		 16M 16M 21.75M 6.04K 6.04M 13.92M 455.87M
Weighted Average Basic & Diluted Shares Outstanding		 16M 16M 21.75M 21.75M 3.65M 23.65M 563.34K

Quarterly Income Statements for Universe Pharmaceuticals

No quarterly income statements for Universe Pharmaceuticals are available.

Annual Cash Flow Statements for Universe Pharmaceuticals

This table details how cash moves in and out of Universe Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Change in Cash & Equivalents		 -3.01 6.88 -1.98 -2.37 -426 24,212 4,094
Net Cash From Operating Activities		 13 6.12 -2.06 -1.30 1,117 -9,507 -5,052
Net Cash From Continuing Operating Activities		 13 6.12 -2.06 -1.30 1,117 -9,507 -5,052
Net Income / (Loss) Continuing Operations		 7.55 7.56 11 -7.91 -6,581 -8,727 -3,672
Consolidated Net Income / (Loss)		 7.55 7.56 11 -7.91 -6,581 -8,727 -3,672
Depreciation Expense		 0.42 0.41 0.45 0.53 509 486 517
Non-Cash Adjustments To Reconcile Net Income		 0.11 0.02 -3.19 2.93 -219 -584 -1,135
Changes in Operating Assets and Liabilities, net		 5.12 -1.88 -11 3.14 7,408 -681 -763
Net Cash From Investing Activities		 -0.09 -0.05 -27 -3.91 -44 -361 -342
Net Cash From Continuing Investing Activities		 -0.09 -0.05 -27 -3.91 -44 -361 -342
Purchase of Property, Plant & Equipment		 -0.09 -0.05 -0.44 -0.09 -44 -208 -267
Acquisitions		 - 0.00 0.00 -3.81 0.00 -117 -80
Sale of Property, Plant & Equipment		 0.00 0.00 0.00 0.00 0.00 1.80 5.38
Other Investing Activities, net		 0.00 0.00 -13 0.00 0.00 -37 0.00
Net Cash From Financing Activities		 -16 0.47 27 3.32 -1,391 33,954 9,726
Net Cash From Continuing Financing Activities		 -16 0.47 27 3.32 -1,391 33,954 9,726
Repayment of Debt		 -3.05 -0.52 -3.68 -4.27 -7,062 1,167 -12,331
Issuance of Debt		 3.06 1.43 4.30 7.59 5,671 7,787 7,057
Issuance of Common Equity		 0.00 0.00 29 0.00 0.00 25,000 15,000
Other Net Changes in Cash		 - - - - -108 126 -238
Cash Interest Paid		 0.14 0.16 0.15 0.20 190 305 289
Cash Income Taxes Paid		 2.26 2.17 3.27 2.75 864 0.00 0.00

Quarterly Cash Flow Statements for Universe Pharmaceuticals

No quarterly cash flow statements for Universe Pharmaceuticals are available.

Annual Balance Sheets for Universe Pharmaceuticals

This table presents Universe Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Total Assets		 29 70 60 42 67,953 69,303
Total Current Assets		 23 50 42 25 51,638 53,604
Cash & Equivalents		 10 8.08 5.71 5.29 29,498 33,592
Accounts Receivable		 11 16 15 13 18,572 15,289
Inventories, net		 1.91 5.20 2.22 3.52 2,715 4,683
Prepaid Expenses		 0.00 0.17 1.72 0.04 852 40
Plant, Property, & Equipment, net		 4.43 4.68 4.25 3.70 3,568 3,584
Total Noncurrent Assets		 1.10 15 14 13 12,748 12,116
Long-Term Investments		 0.74 0.74 0.70 0.69 712 702
Intangible Assets		 0.17 0.18 0.16 0.15 263 297
Other Noncurrent Operating Assets		 0.00 13 12 11 11,772 11,117
Total Liabilities & Shareholders' Equity		 29 70 60 42 67,953 69,303
Total Liabilities		 8.00 11 13 14 22,450 13,174
Total Current Liabilities		 8.00 11 13 14 20,313 13,174
Short-Term Debt		 2.65 4.33 3.94 5.48 5,857 9,257
Accounts Payable		 3.65 5.33 3.08 7.30 5,268 1,932
Current Deferred & Payable Income Tax Liabilities		 1.33 1.10 0.17 0.43 1,021 641
Other Current Liabilities		 - - 3.38 0.54 8,167 1,344
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 2,137 0.00
Long-Term Debt		 - - - 0.00 2,137 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 21 59 46 28 45,503 56,130
Total Preferred & Common Equity		 21 59 46 28 45,503 56,130
Total Common Equity		 21 59 46 28 45,503 56,130
Common Stock		 3.73 29 29 29 54,347 69,347
Retained Earnings		 14 25 16 -1.44 -10,172 -13,844
Accumulated Other Comprehensive Income / (Loss)		 0.90 2.09 -1.67 -2.37 -1,112 -1,814
Other Equity Adjustments		 2.44 2.44 2.44 2.44 2,440 2,440

Quarterly Balance Sheets for Universe Pharmaceuticals

No quarterly balance sheets for Universe Pharmaceuticals are available.

Annual Metrics And Ratios for Universe Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Universe Pharmaceuticals' official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
DEI Shares Outstanding		 0.00 0.00 21,750,000.00 21,750,000.00 3,645,974.00 3,645,974.00 3,645,974.00
DEI Adjusted Shares Outstanding		 0.00 0.00 6,042.00 6,042.00 6,077.00 6,077.00 6,077.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 1,878.65 -1,309.11 -1,082,939.61 -1,436,119.47 -604,254.57
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -7.60% 56.27% -16.34% 80,383.80% -28.74% -22.44%
EBITDA Growth		 0.00% 3.87% 35.03% -145.57% -57,274.33% -100.08% 66.08%
EBIT Growth		 0.00% 4.12% 36.09% -150.96% -60,178.50% -87.41% 61.60%
NOPAT Growth		 0.00% 0.07% 47.32% -143.69% -56,401.64% -102.21% 63.64%
Net Income Growth		 0.00% 0.09% 50.18% -169.68% -83,102.59% -32.61% 57.92%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -83,102.59% -32.61% 98.71%
Operating Cash Flow Growth		 0.00% -53.69% -133.62% 36.69% 85,903.14% -951.26% 46.86%
Free Cash Flow Firm Growth		 0.00% 0.00% -234.94% 129.68% -55,653.44% -941.24% 65.90%
Invested Capital Growth		 0.00% 0.00% 221.76% -24.32% -10.70% 84,524.64% 33.52%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 40.35% 45.90% 52.78% 54.53% 31.93% 26.37% 35.28%
EBITDA Margin		 30.31% 34.07% 29.44% -16.03% -11.43% -32.09% -14.04%
Operating Margin		 29.35% 33.23% 28.32% -17.49% -12.28% -34.83% -16.33%
EBIT Margin		 29.05% 32.74% 28.51% -17.36% -13.00% -34.20% -16.93%
Profit (Net Income) Margin		 22.73% 24.62% 23.66% -19.70% -20.37% -37.90% -20.56%
Tax Burden Percent		 78.23% 74.83% 82.98% 111.49% 152.08% 107.47% 100.00%
Interest Burden Percent		 100.00% 100.49% 100.00% 101.78% 102.99% 103.13% 121.43%
Effective Tax Rate		 21.77% 25.17% 17.24% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 120.65% 42.14% -13.74% -9,518.62% -48.16% -7.51%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 122.52% 41.35% 3.97% 37,807.15% -20.13% -0.60%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -47.98% -13.67% -1.27% -8,169.34% 9.82% 0.28%
Return on Equity (ROE)		 0.00% 72.67% 28.47% -15.01% -17,687.96% -38.34% -7.23%
Cash Return on Invested Capital (CROIC)		 0.00% -79.35% -63.02% 13.96% -9,507.31% -247.69% -36.21%
Operating Return on Assets (OROA)		 0.00% 34.89% 27.65% -10.75% -8,298.51% -23.16% -4.41%
Return on Assets (ROA)		 0.00% 26.24% 22.94% -12.20% -12,997.71% -25.67% -5.35%
Return on Common Equity (ROCE)		 0.00% 72.67% 28.47% -15.01% -17,687.96% -38.34% -7.23%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 36.33% 19.26% -17.03% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 7.63 7.63 11 -4.91 -2,776 -5,614 -2,041
NOPAT Margin		 22.96% 24.86% 23.44% -12.24% -8.59% -24.38% -11.43%
Net Nonoperating Expense Percent (NNEP)		 0.00% -1.87% 0.79% -17.71% -47,325.77% -28.03% -6.90%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -9.75% -8,299.12% -10.49% -3.12%
Cost of Revenue to Revenue		 59.65% 54.10% 47.22% 45.47% 68.07% 73.63% 64.72%
SG&A Expenses to Revenue		 9.14% 10.61% 13.07% 52.98% 29.16% 48.04% 47.85%
R&D to Revenue		 1.86% 1.90% 11.39% 19.04% 15.04% 13.16% 3.76%
Operating Expenses to Revenue		 11.00% 12.51% 24.46% 72.02% 44.20% 61.20% 54.31%
Earnings before Interest and Taxes (EBIT)		 9.65 10 14 -6.97 -4,202 -7,874 -3,024
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 10 10 14 -6.44 -3,693 -7,389 -2,507
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 1.20 1.26 0.26 0.12 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 1.21 1.26 0.27 0.12 0.00 0.00
Price to Revenue (P/Rev)		 0.75 0.81 1.54 0.31 0.00 0.00 0.00
Price to Earnings (P/E)		 3.36 3.38 6.53 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 29.80% 29.63% 15.32% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.33 1.37 0.00 0.11 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.55 1.16 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 1.61 3.96 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 1.68 4.09 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 2.21 4.97 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 2.76 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.13 0.07 0.08 0.20 0.18 0.16
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.05 0.00
Financial Leverage		 0.00 -0.39 -0.33 -0.32 -0.22 -0.49 -0.46
Leverage Ratio		 0.00 1.38 1.24 1.23 1.36 1.49 1.35
Compound Leverage Factor		 0.00 1.39 1.24 1.25 1.40 1.54 1.64
Debt to Total Capital		 0.00% 11.28% 6.85% 7.81% 16.39% 14.94% 14.16%
Short-Term Debt to Total Capital		 0.00% 11.28% 6.85% 7.81% 16.39% 10.95% 14.16%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 4.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 88.72% 93.15% 92.19% 83.61% 85.06% 85.84%
Debt to EBITDA		 0.00 0.25 0.31 -0.61 0.00 -1.08 -3.69
Net Debt to EBITDA		 0.00 -0.78 -1.29 2.43 0.00 3.01 9.99
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.29 0.00
Debt to NOPAT		 0.00 0.35 0.39 -0.80 0.00 -1.42 -4.54
Net Debt to NOPAT		 0.00 -1.07 -1.62 3.18 0.00 3.96 12.27
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.38 0.00
Altman Z-Score		 0.00 5.40 6.47 1.81 442.45 0.30 0.53
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 2.91 4.50 3.17 1.84 2.54 4.07
Quick Ratio		 0.00 2.62 3.36 2.60 1.33 2.37 3.71
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.02 -17 4.99 -2,773 -28,873 -9,846
Operating Cash Flow to CapEx		 15,347.31% 11,805.78% -462.50% -1,389.02% 2,528.41% -4,603.36% -1,932.86%
Free Cash Flow to Firm to Interest Expense		 0.00 -40.57 -165.53 30.74 -17.69 -103.80 -42.43
Operating Cash Flow to Interest Expense		 102.14 49.41 -20.23 -8.01 7.12 -34.18 -21.77
Operating Cash Flow Less CapEx to Interest Expense		 101.48 48.99 -24.61 -8.59 6.84 -34.92 -22.90
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 1.07 0.97 0.62 638.11 0.68 0.26
Accounts Receivable Turnover		 0.00 2.82 3.60 2.59 2,292.97 2.48 1.05
Inventory Turnover		 0.00 8.71 6.38 4.92 7,653.81 12.47 3.12
Fixed Asset Turnover		 0.00 6.93 10.53 8.99 8,127.37 12.89 4.99
Accounts Payable Turnover		 0.00 4.55 5.05 4.34 4,240.79 6.43 3.21
Days Sales Outstanding (DSO)		 0.00 129.24 101.49 140.91 0.16 147.31 346.03
Days Inventory Outstanding (DIO)		 0.00 41.89 57.25 74.23 0.05 29.27 116.82
Days Payable Outstanding (DPO)		 0.00 80.16 72.32 84.05 0.09 56.79 113.69
Cash Conversion Cycle (CCC)		 0.00 90.97 86.42 131.09 0.12 119.80 349.16
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 13 41 31 28 23,287 31,092
Invested Capital Turnover		 0.00 4.85 1.80 1.12 1,107.73 1.98 0.66
Increase / (Decrease) in Invested Capital		 0.00 13 28 -9.91 -3.30 23,259 7,805
Enterprise Value (EV)		 0.00 17 56 -3.34 2.96 -22,215 -25,037
Market Capitalization		 25 25 74 12 3.44 0.89 0.03
Book Value per Share		 $0.00 $1.30 $18.63 $2.14 $1.29 $12,480.33 $123.13
Tangible Book Value per Share		 $0.00 $1.29 $18.57 $2.13 $1.28 $12,408.22 $122.47
Total Capital		 0.00 23 63 50 33 53,497 65,386
Total Debt		 0.00 2.65 4.33 3.94 5.48 7,994 9,257
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 2,137 0.00
Net Debt		 0.00 -8.15 -18 -16 -0.49 -22,216 -25,037
Capital Expenditures (CapEx)		 0.09 0.05 0.44 0.09 44 207 261
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 7.87 22 13 12 7,684 16,095
Debt-free Net Working Capital (DFNWC)		 0.00 18 44 32 17 37,182 49,687
Net Working Capital (NWC)		 0.00 15 39 28 12 31,325 40,430
Net Nonoperating Expense (NNE)		 0.08 0.08 -0.10 3.00 3,805 3,113 1,631
Net Nonoperating Obligations (NNO)		 0.00 -8.15 -18 -16 -0.45 -22,216 -25,037
Total Depreciation and Amortization (D&A)		 0.42 0.41 0.45 0.53 509 486 517
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 25.62% 45.44% 33.59% 0.04% 33.37% 90.12%
Debt-free Net Working Capital to Revenue		 0.00% 58.38% 90.88% 80.57% 0.05% 161.49% 278.22%
Net Working Capital to Revenue		 0.00% 49.76% 81.84% 70.77% 0.04% 136.05% 226.39%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($1,440.00) ($1,020.00) ($626.96) ($8.06)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 3.63M 6.04K 6.04K 13.92K 455.87M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($626.96) ($8.06)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 3.63M 6.04K 6.08K 13.92K 455.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 3.63M 6.04K 6.08K 23.65M 563.34K
Normalized Net Operating Profit after Tax (NOPAT)		 7.63 7.63 11 -4.91 -2,776 -5,614 -1,704
Normalized NOPAT Margin		 22.96% 24.86% 23.44% -12.24% -8.59% -24.38% -9.54%
Pre Tax Income Margin		 29.05% 32.90% 28.51% -17.67% -13.39% -35.27% -20.56%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 74.67 81.21 134.63 -42.92 -26.80 -28.31 -13.03
NOPAT to Interest Expense		 59.02 61.69 110.69 -30.26 -17.71 -20.18 -8.80
EBIT Less CapEx to Interest Expense		 74.01 80.80 130.25 -43.50 -27.08 -29.05 -14.16
NOPAT Less CapEx to Interest Expense		 58.36 61.27 106.32 -30.83 -17.99 -20.92 -9.92
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 211.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 211.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Universe Pharmaceuticals

No quarterly metrics and ratios for Universe Pharmaceuticals are available.


Financials Breakdown Chart

Universe Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Universe Pharmaceuticals' financial year ends in September. Their financial year 2025 ended on September 30, 2025.

Universe Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$3.67 billion in 2025, falling from $7.55 million in 2019. The previous period was -$8.73 billion in 2024. See Universe Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Universe Pharmaceuticals' total operating income in 2025 was -$2.92 billion, based on the following breakdown:
  • Total Gross Profit: $6.30 billion
  • Total Operating Expenses: $9.70 billion

Over the last 6 years, Universe Pharmaceuticals' total revenue changed from $33.23 million in 2019 to $17.86 billion in 2025, a change of 53,643.9%.

Universe Pharmaceuticals' total liabilities were at $13.17 billion at the end of 2025, a 41.3% decrease from 2024, and a 164,545.4% increase since 2020.

In the past 5 years, Universe Pharmaceuticals' cash and equivalents has ranged from $5.29 million in 2023 to $33.59 billion in 2025, and is currently $33.59 billion as of their latest financial filing in 2025.

Over the last 6 years, Universe Pharmaceuticals' book value per share changed from 0.00 in 2019 to 123.13 in 2025, a change of 12,312.6%.


Related Companies

Financial statements for NASDAQ:UPC last updated on 8/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel